Statement of deviation(s) or variation(s) under Reg. 32

To Date: 01st November, 2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Sub: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 32 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 this is to inform the Exchanges that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer (IPO) of the Company during the quarter ended on 30th September, 2026. Please find enclosed herewith a statement in this regard. This is for the information and records of the Exchanges, please. Thanking you. Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: as above Statement of Deviation or Variation in utilization of funds raised Name of listed entity Sai Parenterals Limited Mode of Fund Raising Initial Public Offer (IPO) Type of Instrument Equity Date of Raising Funds 24 March 2026 to 27 March 2026 (Anchor Issue date: 23rd March 2026) Amount Raised 2,850 million Report filed for Quarter ended Quarter ended as on 30th September, 2026. Monitoring Agency Applicable Monitoring Agency Name, if applicable M/s. India Ratings & Research Private Limited Is there a Deviation / Variation in use of funds raised No If yes, whether the same is pursuant to change in terms of a contract or objects, which Not applicable was approved by the shareholders If Yes, Date of shareholder Approval Not applicable Explanation for the Deviation / Variation Not applicable Comments of the Audit Committee after review NIL Comments of the auditors, if any NIL Sr. Original Object Modified Object, if Original Modified Funds Amount of Deviation/ Remarks No any Allocation allocation, Utilised Variation for the if (in if any (in quarter according to any Millions) Millions) pplicable object 1. Capacity expansion upgradation of Not Applicable 1107.95 269.61 98.51 NA -- manufacturing facilities 2. 60% equity in Saicriti Capacity expansion Pharma, to construct a new critical-care upgradation of 0 838.34 100 NA injectable facility at manufacturing Gummadidala, outside facilities the ORR 3. 60% equity in Prathyak Establishment of a Laboratories, an 180.23 0 150 NA -- new R&D Centre operating R&D centre at Genome Valley 4. Repayment / p- repayment- of certain Not Applicable 143.02 0 136.54 NA -- outstanding borrowings 5. Working capital Not Applicable 330.00 0 330.00 NA -- requirements 6. Repayment of bridge loan and term loan availed for Not Applicable 356.41 0 356.41 NA -- investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia) 7. General Corporate Not Applicable 447.40 0 217.57 NA -- Purposes 8. Issue Related Not Applicable 284.99 0 284.90 NA -- Expenses